



COMPANY OVERVIEW

ITUS Corporation is developing a platform called Cchek™, a series of inexpensive non-invasive blood tests for the early detection of cancer.

RECENT NEWS

ITUS Presentation to Special Meeting of Stockholders

Apr 2 2018, 7:00 AM EDT

ITUS and Seramatrix Announce Results of a Blinded Prostate Cancer Study

Mar 27 2018, 7:00 AM EDT

ITUS Announces Issuance of Second Key Cancer Detection Technology Patent

Mar 26 2018, 7:00 AM EDT

STOCK OVERVIEW

| | |
|---------------|-------------------|
| Symbol | ITUS |
| Exchange | NASDAQ |
| Shares OS | 16,631,191 |
| Market Cap | \$66.19M |
| Last Price | \$3.98 |
| 52-Week Range | \$0.6001 - \$6.43 |

INVESTOR RELATIONS

Mike Catelani
Chief Operating Officer
T: 408-708-9808
mcatelani@ituscorp.com

MANAGEMENT TEAM

Dr. Amit Kumar, Ph.D

Chairman, President & Chief Executive Officer

Michael Catelani

Chief Operating Officer and Chief Financial Officer

John Roop

Senior Vice President of Engineering

Anthony Campisi

Vice President of Engineering

ITUS CORPORATION

3150 Almaden Expressway
Suite 250
San Jose, CA 95118
US

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.